Everything below concerns Lyophilized powder. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
== Legislation == The plight of patients with rare diseases became an important political issue in the late 1970s and early 1980s. The US government was subject to pressure from activist groups such as NORD and many others. The chief sponsor of the bill (H.R. 5238) was Henry Waxman (sometimes referred to as the author of the Act), chairman of the Energy and Commerce Subcommittee on Health. It passed the House of Representatives on 14 December 1982, and was similarly approved by voice vote in the Senate on 17 December. On 4 January 1983, President Ronald Reagan signed the ODA into law. Under the ODA drugs, vaccines, and diagnostic agents would qualify for orphan status if they were intended to treat a disease affecting less than 200,000 American citizens. In order to encourage the development of drugs for orphan diseases, the ODA included a number of incentives including seven-year market exclusivity for companies that developed orphan drug, tax credits equal to half of the development costs, later changed to a fifteen-year carry-forward provision and a three-year carry-back that can be applied in profitable year, grants for drug development, fast-track approvals of drugs indicated for rare diseases, and expanded access to the Investigational New Drug Program. The law was also later amended to waive user fees charged under PDUFA. Market exclusivity is particularly appealing to pharmaceutical firms as an incentive to pursue orphan drug development.
Clinical and Vaccine Immunology (CVI) was a peer-reviewed journal published by the American Society for Microbiology. CVI enhances our understanding of the immune response in health and disease by showcasing important clinically relevant research, including new animal models for human immunologic diseases, viral immunology, immunopathogenesis, and clinical laboratory immunology. In particular, the journal highlights important discoveries in immunization and vaccine research, such as the development and evaluation of vaccines, human and animal immune responses to vaccines, vaccine vectors, adjuvants and immunomodulators, quantitative assays of vaccine efficacy, and clinical trials. The journal publishes primary research articles, editorials, commentaries, minireviews, and case reports. Articles are freely accessible after six months (delayed open access). Through its "Global Outreach Program", free online access is available to qualified microbiologists in eligible developing countries.
== Pharmacodynamic properties == Naloxegol inhibits opioid binding in μ-opioid receptors in the gastrointestinal tract, thus decreasing the constipating effects (slowing of gastrointestinal motility and transit, hypertonicity, increased fluid reabsorption) associated with opioids. If naloxegol is coadministered with other opioid antagonists, there is a potential for additive effect and increased risk of opioid withdrawal.
McGregor starred in Moulin Rouge! (2001) as the young poet Christian, who falls in love with the terminally-ill courtesan Satine (Nicole Kidman), for which his performance was widely praised and garnered McGregor his first Golden Globe Award for Best Actor – Motion Picture Musical or Comedy nomination. He also appeared in Ridley Scott's war film Black Hawk Down (2001) as John Grimes. He starred alongside Renée Zellweger in Down with Love (2003). He also portrayed the younger Edward Bloom in Tim Burton's critically acclaimed film Big Fish (2003) alongside Albert Finney, Jessica Lange, Alison Lohman and Billy Crudup. In the same period, he also received critical acclaim for his portrayal of an amoral drifter mixed up with murder in the drama Young Adam (also 2003), which co-starred Tilda Swinton. McGregor voiced the robot Rodney Copperbottom in Robots and the lead character in Gary Chapman's Valiant (both 2005). Also around this time, McGregor played two roles – one a clone of the other – opposite Scarlett Johansson in Michael Bay's science fiction action thriller film The Island (2005). He also headlined Marc Forster's 2005 film Stay, a psychological thriller co-starring Naomi Watts and Ryan Gosling.
Sources: en.wikipedia.org
=== Pharmacokinetics === N-Desalkylflurazepam has an elimination half-life of 47–150 hours (up to 200 hours in some healthy volunteers), with an average of ~71 hours. Peak blood concentrations of N-Desalkylflurazepam is reached at 10.2 h following a single 15 mg dose of Flurazepam, typically around ~10-20.4 ng/mL. Its plasma levels are unreliable amongst patients, and are largely influenced by liver disease, liver enzyme inducers and inhibitors, as well as old age (in men).
Wenzel Model was developed to calculate the dependence that surface roughness has on the observed contact angle. Surfaces that are not atomically smooth will exhibit an observed contact angle that varies from the actual contact angle of the surface. The equation is expressed as:
== Epidemiology == The most common cause of Bornholm disease, Coxsackie B virus, is shed in large amounts in the feces of infected persons and is spread primarily through the fecal-oral route. Respiratory secretions and oral-oral methods have also shown to be modes of transmission. In previous cases the disease has been spread by sharing drink containers, and has been contracted by laboratory personnel working with the virus. The pharynx is typically the initial site for entering the body, however the virus will proliferate in lymphatic tissues and use the blood stream to reach the muscles and produce symptoms. Preventative measures to decrease transmission of the virus causing Bornholm disease emphasize hand hygiene. In previous studies of Bornholm disease the majority of the patients affected were children.
Sources: en.wikipedia.org
=== United States === In the United States, the addition of pure thujone to foods is not permitted. Foods or beverages that contain Artemisia species, white cedar, oakmoss, tansy, or yarrow, must be thujone-free, which in practice means that they contain less than 10 parts per million thujone. Other herbs that contain thujone have no restrictions. For example, sage and sage oil (which can be up to 50% thujone) are on the Food and Drug Administration's list of generally recognized as safe (GRAS) substances. Absinthe offered for sale in the United States must be thujone-free by the same standard that applies to other beverages containing Artemisia, so absinthe with small amounts of thujone may be legally imported.
Vaccine therapies are a type of specific active immunotherapy. Vaccine therapies deliver various agents that will lead to a specific immune response e.g. antibody development or CTL response. Tumor antigens have been a main target in specific active immunotherapy by way of vaccination. Tumor antigens are antigens produced by tumor cells and can be common among patients with the same cancer-type, or unique to a particular patient. Their specificity to malignant tumor cells makes tumor antigens ideal candidates for vaccination. Cancer vaccine C-Met#Active immunotherapy, Mantle cell lymphoma Immunotherapy,
Lactobacillales (order) as the most abundant; primarily upstream of pnuC, and sometimes pncB or pnuC–nadR operons. Notable organisms include species of Fructobacillus and many other lactic acid bacteria. Planctomycetota (phylum), commonly upstream of nadA. Pseudomonadota, found in Pseudomonas laurylsulfatiphila and related species, upstream of an annotated nucleoside transporter. Actinobacteriota, in isolated instances from metagenome-assembled genomes. The prevalence of mini-NAD⁺-II riboswitches in lactic acid bacteria is thought to be functionally significant, as these organisms rely on various anaerobic fermentation strategies (e.g., lactic acid or ethanol production) to maintain a balanced NAD⁺/NADH ratio. The prevalence of mini-NAD⁺-II riboswitches in lactic acid bacteria is thought to be functionally significant, as these organisms rely on various anaerobic fermentation strategies (e.g., lactic acid or ethanol production) to maintain a balanced NAD⁺/NADH ratio.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.